Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

FDMO provides disciplined momentum exposure with a balanced sector allocation, favoring mega-cap tech leaders. Click here to ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,899.40 today based on a price of $781.99 for LLY at the time of writing.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Johnson & Johnson beat quarterly sales expectations and is raising its outlook for the year, despite the threat of increased tariffs on the pharmaceutical industry.

CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 - Amphista Therapeutics ('the Company” or 'Amphista”), a leader in the discovery of ...

Patients with migraine spontaneously described typical symptoms like pain but only revealed cognitive symptoms after being asked further questions, according to a speaker at the American Headache ...